SCP
VRX

Syntal Capital Partners’s VALEANT PHARMACEUTICALS INTL VRX Stock Holding History

Syntal Capital Partners’s Portfolio VRX Stock Details VRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-9,500
Closed -$380K – 241
2019
Q3 		$380K Buy
+9,500
New +$380K 0.1% 155

Syntal Capital Partners's VRX Position: Q4 2019 in Review

Syntal Capital Partners sold out of VALEANT PHARMACEUTICALS INTL (VRX) in Q4 2019, closing a stake of 9,500 shares — an estimated $380K sold.

Syntal Capital Partners first reported a position in VRX in Q3 2019 and held it in 1 quarter. The position peaked at $380K in Q3 2019. 0 funds tracked by Wall St. Rank hold VRX as of Q4 2019.

  • Syntal Capital Partners reported no remaining VALEANT PHARMACEUTICALS INTL position as of Q4 2019 after selling out during the quarter.
  • Syntal Capital Partners sold 9,500 VALEANT PHARMACEUTICALS INTL shares in Q4 2019, an estimated $380K.
  • Syntal Capital Partners first reported a position in VALEANT PHARMACEUTICALS INTL in Q3 2019 and held it in 1 quarter.
  • Syntal Capital Partners's VALEANT PHARMACEUTICALS INTL position peaked at $380K in Q3 2019.
  • 0 funds tracked by Wall St. Rank held VALEANT PHARMACEUTICALS INTL as of Q4 2019.

Based on Syntal Capital Partners's 13F filing for Q4 2019, filed 10 Feb 2020.